HK1214622A1 - 含用於純化芳基硫酸酯酶a的方法 - Google Patents

含用於純化芳基硫酸酯酶a的方法 Download PDF

Info

Publication number
HK1214622A1
HK1214622A1 HK16102496.7A HK16102496A HK1214622A1 HK 1214622 A1 HK1214622 A1 HK 1214622A1 HK 16102496 A HK16102496 A HK 16102496A HK 1214622 A1 HK1214622 A1 HK 1214622A1
Authority
HK
Hong Kong
Prior art keywords
chromatography
asa
protein
column
ultrafiltration
Prior art date
Application number
HK16102496.7A
Other languages
English (en)
Chinese (zh)
Inventor
‧尼科爾斯
D‧尼科尔斯
‧基農尼斯‧加西亞
I‧基农尼斯‧加西亚
‧鄭
B‧L‧郑
‧蔣
M‧H‧蒋
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HK1214622A1 publication Critical patent/HK1214622A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16102496.7A 2013-01-09 2014-01-09 含用於純化芳基硫酸酯酶a的方法 HK1214622A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
US61/750,693 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Publications (1)

Publication Number Publication Date
HK1214622A1 true HK1214622A1 (zh) 2016-07-29

Family

ID=50002885

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102496.7A HK1214622A1 (zh) 2013-01-09 2014-01-09 含用於純化芳基硫酸酯酶a的方法

Country Status (12)

Country Link
US (3) US11407984B2 (cg-RX-API-DMAC7.html)
EP (1) EP2943568B1 (cg-RX-API-DMAC7.html)
JP (5) JP6427502B2 (cg-RX-API-DMAC7.html)
CN (4) CN119979504A (cg-RX-API-DMAC7.html)
AU (3) AU2014205441B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015015948B1 (cg-RX-API-DMAC7.html)
CA (1) CA2896979C (cg-RX-API-DMAC7.html)
EA (1) EA030551B1 (cg-RX-API-DMAC7.html)
ES (1) ES2768261T3 (cg-RX-API-DMAC7.html)
HK (1) HK1214622A1 (cg-RX-API-DMAC7.html)
MX (2) MX372711B (cg-RX-API-DMAC7.html)
WO (1) WO2014110246A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729566B1 (en) * 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
JP6427502B2 (ja) 2013-01-09 2018-11-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａの精製方法
US20160176921A1 (en) * 2014-12-22 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
MX2018011162A (es) 2016-03-16 2018-11-22 Phoenix Tissue Repair Inc Metodos de purificacion de colageno 7.
JP6957738B2 (ja) * 2017-08-31 2021-11-02 グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． スルファターゼタンパク質を精製する方法
EP3728572A1 (en) * 2017-12-19 2020-10-28 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
KR20200118011A (ko) * 2018-02-02 2020-10-14 엔지반트 테라퓨틱스 게엠베하 파버병을 치료하는 방법
EP3774894A1 (en) * 2018-04-12 2021-02-17 Amgen Inc. Methods for making stable protein compositions
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
MX2022006987A (es) * 2019-12-12 2022-07-13 Lilly Co Eli Metodos para la inactivacion viral mediante detergentes compatibles con el medioambiente.
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
WO1999037325A2 (en) 1998-01-27 1999-07-29 Hemebiotech A/S Method for treating acute intermittent porphyria (aip) and other porphyric diseases
BR9911131A (pt) 1998-06-09 2001-03-06 Statens Seruminstitut Processo para produção de imunoglobulinas para administração intravenosa e outros produtos de imunoglobulina
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
WO2001007065A2 (en) 1999-07-27 2001-02-01 Hemebiotech A/S PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002040686A2 (en) 2000-11-15 2002-05-23 Genzyme Corporation Expression system for recombinant proteins
AU2002317701A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
AU2003212912A1 (en) 2002-02-04 2003-09-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
NZ548871A (en) * 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
BRPI0709737A2 (pt) 2006-04-04 2011-07-26 Zymenex As processo para concentraÇço de um polipeptÍdeo
MX2011004558A (es) * 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
SI2585104T1 (sl) 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postopki in sestavki za dostavo arilsulfataze A
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
JP6427502B2 (ja) 2013-01-09 2018-11-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａの精製方法

Also Published As

Publication number Publication date
AU2014205441B2 (en) 2019-12-12
EA201590826A1 (ru) 2015-11-30
MX2015008875A (es) 2015-10-22
CA2896979C (en) 2023-05-02
JP7407161B2 (ja) 2023-12-28
US20230235303A1 (en) 2023-07-27
MX2020003798A (es) 2020-08-03
ES2768261T3 (es) 2020-06-22
JP2020015750A (ja) 2020-01-30
JP2022023225A (ja) 2022-02-07
EP2943568B1 (en) 2019-11-20
WO2014110246A1 (en) 2014-07-17
CN119979504A (zh) 2025-05-13
EP2943568A1 (en) 2015-11-18
JP7663649B2 (ja) 2025-04-16
BR112015015948B1 (pt) 2022-05-17
CN120665836A (zh) 2025-09-19
CA2896979A1 (en) 2014-07-17
US20150353904A1 (en) 2015-12-10
HK1216429A1 (en) 2016-11-11
EA030551B1 (ru) 2018-08-31
AU2020201079A1 (en) 2020-03-05
AU2020201079B2 (en) 2022-05-26
US12319940B2 (en) 2025-06-03
US20240392268A1 (en) 2024-11-28
AU2014205441A1 (en) 2015-06-25
MX372711B (es) 2020-04-21
AU2022221475B2 (en) 2025-05-22
CN104903442A (zh) 2015-09-09
JP6427502B2 (ja) 2018-11-21
JP2024001160A (ja) 2024-01-09
BR112015015948A2 (cg-RX-API-DMAC7.html) 2017-08-15
US11884945B2 (en) 2024-01-30
AU2022221475A1 (en) 2022-09-22
JP2018171067A (ja) 2018-11-08
US11407984B2 (en) 2022-08-09
CN112126634A (zh) 2020-12-25
JP2016504040A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
JP7407161B2 (ja) アリールスルファターゼａの精製方法
JP7594365B2 (ja) 組換えイズロン酸２スルファターゼの精製
US20200040317A1 (en) Methods for purification of arylsulfatase a
WO2024176112A1 (en) Large scale production of recombinant arylsulfatase a and compositions thereof
HK1216429B (en) Methods for purification of arylsulfatase a